1
|
Guibert C, Amoura L, Rakotoarisoa L, Plat F, Sonnet E, Lablanche S, Tréglia C, Sarde E, Leca V, Rimareix F, Melki V, Baucher F, Betari B, Meyer L, Kessler L. MiniMed TM 780G Advanced Hybrid Closed-Loop System Study in Pregnant Women with Type 1 Diabetes. Diabetes Technol Ther 2023; 25:893-901. [PMID: 37956265 DOI: 10.1089/dia.2023.0267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
Abstract
Background: Evaluate the impact of the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system on the glucose profile of pregnant women with type 1 diabetes (T1D) and maternal-neonatal complications. Methods: From April 2021 to September 2022, pregnant women with T1D treated with the AHCL system were included in an observational multicenter retrospective study. Continuous glucose monitoring parameters were analyzed monthly during pregnancy as well as maternal-neonatal complications. Results: Thirteen pregnant women, including a twin pregnancy (age: 33 ± 3 years, hemoglobin A1c [HbA1c]: 7.3% ± 0.7%, insulin doses: 0.72 ± 0.21 U/kg/day) were analyzed. At delivery, gestational age was 37 ± 2 weeks. During first 2 weeks of pregnancy, time in range (TIR, 63-140 mg/dL) was 46% (34-55) and increased to 54% (51-59) (P < 0.01), 64% (48-68) (P < 0.01), and 66% (60-70) (P < 0.001) during the first, second, and third trimester, respectively. During the night, TIR (63-140 mg/dL) was >70% throughout pregnancy. Time below the range <63 mg/dL increased from 0.5% (0-2) to 1.3% (0.7-2.2), 2% (1.2-3.5) (P < 0.05), and 1.3% (1.31-3) (P < 0.05) during the first, second, and third trimester, respectively. At delivery, insulin doses increased to 0.89 ± 0.35 IU/kg/day (P < 0.01), and HbA1c decreased to 6.4% ± 0.6% (P = 0.005). The reported carbohydrate amount increased from 167 ± 363 g/d during early pregnancy to 243 ± 106 g/d (P < 0.01) at delivery. The birthweight was 3134 ± 711 g, with 5/14 macrosomia and 2/14 neonatal hypoglycemia. Moreover, 5/13 patients had a preeclampsia and 9/13 a cesarean section, including three cases of scarred uterus. The Clinical Trial Registration number is: CE-2022-55. Conclusion: The AHCL system provided good glucose control during pregnancy and recommendation targets were reached during the nocturnal period only. The maternal and neonatal complications remained high.
Collapse
Affiliation(s)
- Clara Guibert
- Obstetrics and Gynecology Department, Diabetes, and Nutrition Department, University Hospital of Strasbourg, Strasbourg, France
| | - Lamia Amoura
- Endocrinology, Diabetes, and Nutrition Department, University Hospital of Strasbourg, Strasbourg, France
| | - Luc Rakotoarisoa
- Endocrinology, Diabetes, and Nutrition Department, University Hospital of Strasbourg, Strasbourg, France
- Regenerative Nanomedicine, Inserm UMR 1260, University of Strasbourg, Strasbourg, France
| | - Francoise Plat
- Department of Endocrinology and Metabolic Diseases, Hospital of Avignon, Avignon, France
| | - Emmanuel Sonnet
- Department of Endocrinology, University Hospital of Brest, Brest, France
| | - Sandrine Lablanche
- Department of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, Grenoble, France
| | - Clémence Tréglia
- Department of Endocrinology, Conception Hospital, Marseille University Hospital, Marseille, France
| | - Elisa Sarde
- Endocrinology, Diabetes, and Nutrition Department, Hospital of Rayettes, Martigues, France
| | - Viviane Leca
- Endocrinology, Diabetes, and Nutrition Department, Hospital of Rayettes, Martigues, France
| | - Frédérique Rimareix
- Department of Endocrinology and Metabolic Diseases, Rangueil University Hospital, Toulouse, France
| | - Vincent Melki
- Department of Endocrinology and Metabolic Diseases, Rangueil University Hospital, Toulouse, France
| | - Franciane Baucher
- Department of Endocrinology, Saint Roch Medical Center, Cabestany, France
| | - Bouchra Betari
- Department of Endocrinology, Sud Francilien Hospital, Corbeil-Essonnes, France
| | - Laurent Meyer
- Endocrinology, Diabetes, and Nutrition Department, University Hospital of Strasbourg, Strasbourg, France
| | - Laurence Kessler
- Endocrinology, Diabetes, and Nutrition Department, University Hospital of Strasbourg, Strasbourg, France
- Regenerative Nanomedicine, Inserm UMR 1260, University of Strasbourg, Strasbourg, France
| |
Collapse
|
2
|
Notemi LM, Amoura L, Fall Mostaine F, Meyer L, Paris D, Talha S, Pottecher J, Kessler L. Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study. J Clin Transl Endocrinol 2022; 30:100306. [PMID: 36238800 PMCID: PMC9550647 DOI: 10.1016/j.jcte.2022.100306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 08/22/2022] [Accepted: 09/26/2022] [Indexed: 10/25/2022] Open
Abstract
Objective Evaluate the efficacy of a new modality of insulin therapy associating both the sensor-augmented pump therapy with predictive low-glucose management (SAP-PLGM) and a telemedicine follow-up in patients with Type 1 diabetes (T1D) in a real-life setting. Methods T1D adults under Minimed 640G system with a telemedicine follow-up for glucose management were included in a retrospective study. The primary endpoint was HbA1c while continuous glucose monitoring parameters (CGM) and treatment compliance were the secondary endpoints. These parameters were analyzed according to the therapeutic indication, HbA1c ≥ 8 % (Group A) or severe hypoglycemic events (Group B) and in patients switched to SAP-PLGM therapy. Results 62 patients were analyzed with a 28 ± 12 months of follow-up. In Group A, HbA1c decreased from 8.3 ± 0.4 % to 7.7 ± 0.7 % (p < 0.05) and to 7.9 ± 0.3 % (p < 0.05) after 2 and 3 years, respectively. In patients switched to SAP-PLGM therapy, HbA1c decreased from 7.7 ± 0.7 % to 7.2 ± 0.8 % (p < 0.05) at 2 years. After 6 months, the time-below-range (<70 mg/dL) decreased from 2.1 % [0.6-4] to 1.1 % [0.3-2.6] (p < 0.05). Severe hypoglycemic events decreased from 1.62 to 0.5 events/patient/year in Group B (p < 0.05). At 3 years, treatment compliance was 92 % [70-97] in the total population. Conclusions Long-term real-life treatment with the SAP-PLGM therapy combined with telemedicine was associated with improved glycemic control in T1D, along with high treatment compliance.
Collapse
Affiliation(s)
- Léonie Makuété Notemi
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France
| | - Lamia Amoura
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France
| | - Fatéma Fall Mostaine
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France
| | - Laurent Meyer
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France
| | - Dominique Paris
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France
| | - Samy Talha
- Department of Physiology and Functional Explorations, Pole of Thoracic Pathology, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg cedex, France,UR 3072, « Mitochondria, Oxidative Stress and Muscle Protection », CRBS, CS 60026, 1, rue Eugène Boeckel, 67084 Strasbourg Cedex, France
| | - Julien Pottecher
- Anesthesia-intensive Care Department and Peri-Operative Medicine, Hautepierre Hospital, 1, Avenue Molière, 67098 Strasbourg Cedex, France
| | - Laurence Kessler
- Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France,INSERM UMR 1260 - Regenerative Nanomedicine, Organ Dysfunction and Transplantation, University of Strasbourg, Pharmacy Faculty 74 route du Rhin, 67401 Illkirch, France,Corresponding author at: Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, 1 Place de l’Hôpital, 67091 Strasbourg Cedex, France.
| |
Collapse
|
3
|
Meyer L, Flocard M, Fabacher T, Bahougne T, Ortéga F, Paris D, Munch M, Boullu-Sanchis S, Canel C, Chappaz C, Amoura L, Meyer N, Kessler L. Metabolic Benefit of Teleconsultation for Diabetes Management During the COVID-19 Pandemic: A French Observational Prospective Study. Telemed J E Health 2022; 29:612-616. [PMID: 35944265 DOI: 10.1089/tmj.2022.0090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Aim: To investigate the impact of teleconsultation on glycemic control in patients with diabetes during the COVID-19 pandemic. Methods: In this observational prospective study, the main outcome was the comparison of glycated hemoglobin (HbA1c) between patients with or without teleconsultation at 6-month follow-up. Results: From March 17 to May 31, 2020, 610 patients were included, 456 were followed-up using Teleconsultation présent (TC+) and 154 not using No Teleconsultation (TC-). Patients of TC+ Group were younger, 57 ± 17 versus 65 ± 15.5 years (p < 0.001), with a lower body mass index, 28 ± 6.2 kg/m2 versus 30 ± 5.8 kg/m2, compared to those of TC- Group (p < 0.001). HbA1c were comparable between the two groups: 7.35 ± 0.27% for TC+ versus 7.48 ± 0.22% for TC- Group. At 6-month follow-up, HbA1c was lower in TC+ versus TC- Group: 7.21 ± 0.15% versus 7.6 ± 0.18% (p = 0.004). Conclusion: Our findings point toward the feasibility and usefulness of teleconsultation for the follow-up of patients with diabetes in such exceptional circumstances.
Collapse
Affiliation(s)
- Laurent Meyer
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France.,Private Center of Endocrinology and Diabetology, Strasbourg, France
| | - Mathilde Flocard
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | - Thibault Fabacher
- Department of Biostatistic and Public health, University Hospital, Strasbourg, France
| | - Thibault Bahougne
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | - Françoise Ortéga
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | - Dominique Paris
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | - Marion Munch
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | | | - Clémence Canel
- Private Center of Endocrinology and Diabetology, Strasbourg, France
| | - Claire Chappaz
- Private Center of Endocrinology and Diabetology, Strasbourg, France
| | - Lamia Amoura
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France
| | - Nicolas Meyer
- Department of Biostatistic and Public health, University Hospital, Strasbourg, France
| | - Laurence Kessler
- Department of Endocrinology Diabetes and Nutrition, University Hospital, Strasbourg, France.,Inserm UMR 1260, Regenerative Nanomedicine, University of Strasbourg France, Strasbourg, France
| |
Collapse
|
4
|
Dillmann C, Amoura L, Fall Mostaine F, Coste A, Bounyar L, Kessler L. Feasibility of Real-Time Continuous Glucose Monitoring Telemetry System in an Inpatient Diabetes Unit: A Pilot Study. J Diabetes Sci Technol 2022; 16:955-961. [PMID: 33660531 PMCID: PMC9264424 DOI: 10.1177/1932296821994586] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Hospitalization of persons with diabetes in an inpatient diabetes unit is challenging, notably for patients having different profiles. We aimed to evaluate the feasibility and the benefit of a continuous glucose monitoring (CGM) telemetry system to control glucose excursions in hospitalized patients with diabetes, according to their diabetes type and the reasons for their hospitalization. METHOD A prospective pilot study was conducted in 53 insulin-requiring diabetes patients hospitalized in the general ward. Glucose was monitored using Guardian Connect (GC, Medtronic) to adopt insulin therapy. The time in range (TIR, target 70-180 mg/dL), the time below range (TBR), and the time above range (TAR) were recorded by GC between the start of hospitalization (SH) and end of hospitalization (EH), and analyzed according to the diabetes type (type 1 diabetes n = 28, type 2 diabetes n = 25) and the reasons for hospitalization (acute complications n = 35, therapeutic education n = 18). Patient and caregiver satisfaction was also assessed. RESULTS In patients with type 2 diabetes and those hospitalized for acute complications, TIR significantly increased between the SH and EH, from 75.7% (95%CI 48.5-84.6) to 82.2% (95%CI 63.2-91.8) P = 0.043 and from 58.3% (95%CI 46.3-69.7) to 66.4% (95%CI 55.6-75.5) P = 0.031, respectively, and TAR significantly decreased, with no change in TBR. In patients with diabetes hospitalized for therapeutic education, TBR significantly decreased from 3.4% (95%CI 0-9.4) to 0% (95%CI 0-3.8) P = 0.037. Finally, 94% of patients and caregivers deemed the GC system useful. CONCLUSIONS CGM telemetry system use is feasible and well accepted in patients hospitalized in diabetes care unit and could be useful to improve therapeutic education and metabolic control, especially for specific homogenous populations with diabetes.
Collapse
Affiliation(s)
| | - Lamia Amoura
- Department of Diabetology, University
Hospital of Strasbourg, France
| | | | - Adrien Coste
- Department of Diabetology, University
Hospital of Strasbourg, France
| | - Leila Bounyar
- Department of Diabetology, University
Hospital of Strasbourg, France
| | - Laurence Kessler
- Department of Diabetology, University
Hospital of Strasbourg, France
- Inserm UMR 1260, Regenerative
Nanomedicine, University of Strasbourg, France
- Laurence Kessler, MD, PhD, Service
d’Endocrinologie-Diabète-Nutrition, Hôpital Civil, 1 Place de l’Hôpital,
Strasbourg Cedex 67 091, France.
| |
Collapse
|
5
|
Kassem M, El Habhab A, Kreutter G, Amoura L, Baltzinger P, Abbas M, Sbat N, Zobairi F, Schini-Kerth VB, Kessler L, Toti F. In Vitro Impact of Pro-Senescent Endothelial Microvesicles on Isolated Pancreatic Rat Islets Function. Transplant Proc 2021; 53:1736-1743. [PMID: 33934912 DOI: 10.1016/j.transproceed.2021.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 01/15/2021] [Accepted: 02/24/2021] [Indexed: 10/21/2022]
Abstract
BACKGROUND Ischemia-driven islet isolation procedure is one of the limiting causes of pancreatic islet transplantation. Ischemia-reperfusion process is associated with endothelium dysfunction and the release of pro-senescent microvesicles. We investigated whether pro-senescent endothelial microvesicles prompt islet senescence and dysfunction in vitro. MATERIAL AND METHODS Pancreatic islets were isolated from male young rats. Replicative endothelial senescence was induced by serial passaging of primary porcine coronary artery endothelial cells, and microvesicles were isolated either from young passage 1 (P1) or senescent passage 3 (P3) endothelial cells. Islet viability was assessed by fluorescence microscopy, apoptosis by flow cytometry, and Western blot. Function was assessed by insulin secretion and islet senescence markers p53, p21, and p16 by Western blot. Microvesicles were stained by the PKH26 lipid fluorescent probe and their islet integration assessed by microscopy and flow cytometry. RESULTS Regardless of the passage, half microvesicles were integrated in target islets after 24 hours incubation. Insulin secretion significantly decreased after treatment by senescent microvesicles (P3: 1.7 ± 0.2 vs untreated islet: 2.7 ± 0.2, P < .05) without altering the islet viability (89.47% ± 1.69 vs 93.15% ± 0.97) and with no significant apoptosis. Senescent microvesicles significantly doubled the expression of p53, p21, and p16 (P < .05), whereas young microvesicles had no significant effect. CONCLUSION Pro-senescent endothelial microvesicles specifically accelerate the senescence of islets and alter their function. These data suggest that islet isolation contributes to endothelial driven islet senescence.
Collapse
Affiliation(s)
- Mohamad Kassem
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Ali El Habhab
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Guillaume Kreutter
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Lamia Amoura
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Philippe Baltzinger
- Department of Diabetes and Nutrition Endocrinology, University Hospital of Strasbourg, Strasbourg, France
| | - Malak Abbas
- UMR CNRS 7213, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch-Graffenstaden, France
| | - Noura Sbat
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Fatiha Zobairi
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Valérie B Schini-Kerth
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France
| | - Laurence Kessler
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France; Department of Diabetes and Nutrition Endocrinology, University Hospital of Strasbourg, Strasbourg, France
| | - Florence Toti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), Faculty of Medicine, University of Strasbourg, Strasbourg, France.
| |
Collapse
|
6
|
El Habhab A, Altamimy R, Abbas M, Kassem M, Amoura L, Qureshi AW, El Itawi H, Kreutter G, Khemais‐Benkhiat S, Zobairi F, Schini‐Kerth VB, Kessler L, Toti F. Significance of neutrophil microparticles in ischaemia-reperfusion: Pro-inflammatory effectors of endothelial senescence and vascular dysfunction. J Cell Mol Med 2020; 24:7266-7281. [PMID: 32520423 PMCID: PMC7339165 DOI: 10.1111/jcmm.15289] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 02/14/2020] [Accepted: 03/08/2020] [Indexed: 12/15/2022] Open
Abstract
Endothelial senescence is an emerging cause of vascular dysfunction. Because microparticles are effectors of endothelial inflammation and vascular injury after ischaemia-reperfusion, we examined leucocyte-derived microparticles of spleen origin as possible contributors. Microparticles were generated from primary rat splenocytes by either lipopolysaccharide or phorbol-myristate-acetate/calcium ionophore, under conditions mimicking innate and adaptive immune responses. Incubation of primary porcine coronary endothelial cells with either type of microparticles, but not with those from unstimulated splenocytes, leads to a similar threefold raise in senescence-associated β-galactosidase activity within 48 hours, indicating accelerated senescence, to endothelial oxidative stress, and a fivefold and threefold increase in p21 and p16 senescence markers after 24 hours. After 12-hour incubation, the endothelial-dependent relaxation of coronary artery rings was reduced by 50%, at distinct optimal microparticle concentration. In vitro, microparticles were pro-thrombotic by up-regulating the local angiotensin system, by prompting tissue factor activity and a secondary generation of pro-coagulant endothelial microparticles. They initiated an early pro-inflammatory response by inducing phosphorylation of NF-κB, MAP kinases and Akt after 1 hour, and up-regulated VCAM-1 and ICAM-1 at 24 hours. Accordingly, VCAM-1 and COX-2 were also up-regulated in the coronary artery endothelium and eNOS down-regulated. Lipopolysaccharide specifically favoured the shedding of neutrophil- and monocyte-derived microparticles. A 80% immuno-depletion of neutrophil microparticles reduced endothelial senescence by 55%, indicating a key role. Altogether, data suggest that microparticles from activated splenocytes prompt early pro-inflammatory, pro-coagulant and pro-senescent responses in endothelial cells through redox-sensitive pathways. The control of neutrophil shedding could preserve the endothelium at site of ischaemia-reperfusion-driven inflammation and delay its dysfunction.
Collapse
Affiliation(s)
- Ali El Habhab
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Raed Altamimy
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Malak Abbas
- UMR CNRS 7213Laboratory of Biophotonics and PharmacologyFaculty of PharmacyUniversity of StrasbourgIllkirch-GraffenstadenFrance
| | - Mohamad Kassem
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Lamia Amoura
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Abdul Wahid Qureshi
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Hanine El Itawi
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Guillaume Kreutter
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
| | - Sonia Khemais‐Benkhiat
- UMR CNRS 7213Laboratory of Biophotonics and PharmacologyFaculty of PharmacyUniversity of StrasbourgIllkirch-GraffenstadenFrance
| | - Fatiha Zobairi
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
- Faculty of MedicineFederation of Translational Medicine (FMTS)StrasbourgFrance
| | - Valérie B. Schini‐Kerth
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
- Faculty of PharmacyUniversity of StrasbourgIllkirch-GraffenstadenFrance
| | - Laurence Kessler
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
- Department of Diabetes and Nutrition EndocrinologyUniversity Hospital of StrasbourgStrasbourgFrance
- Faculty of MedicineFederation of Translational Medicine (FMTS)StrasbourgFrance
| | - Florence Toti
- INSERM (French National Institute of Health and Medical Research)UMR 1260Regenerative Nanomedicine (RNM)University of StrasbourgIllkirch-GraffenstadenFrance
- Faculty of PharmacyUniversity of StrasbourgIllkirch-GraffenstadenFrance
| |
Collapse
|
7
|
Amoura L, El-Ghazouani FZ, Kassem M, El Habhab A, Kreutter G, Sahraoui S, Bosco D, Jessel N, Berney T, Benhamou PY, Toti F, Kessler L. Assessment of plasma microvesicles to monitor pancreatic islet graft dysfunction: Beta cell- and leukocyte-derived microvesicles as specific features in a pilot longitudinal study. Am J Transplant 2020; 20:40-51. [PMID: 31319009 DOI: 10.1111/ajt.15534] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 06/28/2019] [Accepted: 07/09/2019] [Indexed: 01/25/2023]
Abstract
Markers of early pancreatic islet graft dysfunction and its causes are lacking. We monitored 19 type 1 diabetes islet-transplanted patients for up to 36 months following last islet injection. Patients were categorized as Partial (PS) or complete (S) Success, or Graft Failure (F), using the β-score as an indicator of graft function. F was the subset reference of maximum worsened graft outcome. To identify the immune, pancreatic, and liver contribution to the graft dysfunction, the cell origin and concentration of circulating microvesicles (MVs) were assessed, including MVs from insulin-secreting β-cells typified by polysialic acid of neural cell adhesion molecule (PSA-NCAM), and data were compared with values of the β-score. Similar ranges of PSA-NCAM+ -MVs were found in healthy volunteers and S patients, indicating minimal cell damage. In PS, a 2-fold elevation in PSA-NCAM+ -MVs preceded each β-score drop along with a concomitant rise in insulin needs, suggesting β-cell damage or altered function. Significant elevation of liver asialoglycoprotein receptor (ASGPR)+ -MVs, endothelial CD105+ -MVs, neutrophil CD66b+ -MVs, monocyte CD 14+ -MVs, and T4 lymphocyte CD4+ -MVs occurred before each β-score drop, CD8+ -MVs increased only in F, and B lymphocyte CD19+ -MVs remained undetectable. In conclusion, PSA-NCAM+ -MVs are noninvasive early markers of transplant dysfunction, while ASGPR+ -MVs signal host tissue remodeling. Leukocyte MVs could identify the cause of graft dysfunction.
Collapse
Affiliation(s)
- Lamia Amoura
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France.,CLINICA Group, Contract Research Organization, Alger, Algeria
| | - Fatiha Z El-Ghazouani
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Mohamad Kassem
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Ali El Habhab
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Guillaume Kreutter
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Salah Sahraoui
- CLINICA Group, Contract Research Organization, Alger, Algeria
| | - Domenico Bosco
- Department of Surgery, Islet Isolation, and Transplantation, University Hospitals, Geneva, Switzerland
| | - Nadia Jessel
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Thierry Berney
- Department of Surgery, Islet Isolation, and Transplantation, University Hospitals, Geneva, Switzerland
| | - Pierre-Yves Benhamou
- Department of Endocrinology, Diabetes, and Nutrition, Grenoble Alpes University, Grenoble, France.,Laboratory of Fundamental and Applied Bioenergetics Grenoble, Inserm U1055, Grenoble, France
| | - Florence Toti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Laurence Kessler
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France.,Department of Endocrinology, Diabetes and Nutrition, University Hospital of Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | | |
Collapse
|
8
|
Farooq MA, Gaertner S, Amoura L, Niazi ZR, Park SH, Qureshi AW, Oak MH, Toti F, Schini-Kerth VB, Auger C. Intake of omega-3 formulation EPA:DHA 6:1 by old rats for 2 weeks improved endothelium-dependent relaxations and normalized the expression level of ACE/AT1R/NADPH oxidase and the formation of ROS in the mesenteric artery. Biochem Pharmacol 2019; 173:113749. [PMID: 31830469 DOI: 10.1016/j.bcp.2019.113749] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 12/06/2019] [Indexed: 01/21/2023]
Abstract
Omega-3 polyunsaturated fatty acids (PUFAs) including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to protect the cardiovascular system, in part, by stimulating the endothelial formation of nitric oxide (NO). EPA:DHA 6:1 has been identified as a potent omega 3 PUFA formulation to induce endothelium-dependent vasorelaxation and activation of endothelial NO synthase (eNOS). This study examined whether intake of EPA:DHA 6:1 (500 mg/kg/day) for 2 weeks improves an established endothelial dysfunction in old rats (20 months old), and, if so, the underlying mechanism was subsequently determined. In the main mesenteric artery rings, an endothelial dysfunction characterized by a blunted NO component, an abolished endothelium-dependent hyperpolarization component, and increased endothelium-dependent contractile responses (EDCFs) are observed in old rats compared to young rats. Age-related endothelial dysfunction was associated with increased vascular formation of reactive oxygen species (ROS) and expression of eNOS, components of the local angiotensin system, senescence markers, and cyclooxygenase-2 (COX-2), and the downregulation of COX-1. The EPA:DHA 6:1 treatment improved the NO-mediated relaxation, reduced the EDCF-dependent contractile response and the vascular formation of ROS, and normalized the expression level of all target proteins in the old arterial wall. Thus, the present findings indicate that a 2-week intake of EPA:DHA 6:1 by old rats restored endothelium-dependent NO-mediated relaxations, most likely, by preventing the upregulation of the local angiotensin system and the subsequent formation of ROS.
Collapse
Affiliation(s)
- Muhammad A Farooq
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Sébastien Gaertner
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Hôpitaux Universitaire de Strasbourg (HUS), Service des Maladies Vasculaires - Hypertension Artérielle, 67000 Strasbourg, France
| | - Lamia Amoura
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Zahid R Niazi
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Sin-Hee Park
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Abdul W Qureshi
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Min-Ho Oak
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Florence Toti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France
| | - Valérie B Schini-Kerth
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France; Hôpitaux Universitaire de Strasbourg (HUS), Service des Maladies Vasculaires - Hypertension Artérielle, 67000 Strasbourg, France
| | - Cyril Auger
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg, France; Université de Strasbourg, Faculté de Pharmacie, 67000 Strasbourg, France.
| |
Collapse
|
9
|
Qureshi AW, Altamimy R, El Habhab A, Amoura L, Khemais-Berkhiat S, Kassem M, Farooq MA, Hasan H, Park SH, El Ghazouani F, Auger C, Schini-Kerth VB, Toti F. P2253Intake of the omega 3 PUFAs formulation EPA:DHA 6:1 by aged rats reduced shedding of microvesicles from spleen-derived cultured leukocytes and their ability to promote senescence in endothelial cells. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Ageing is associated with the appearance of endothelial senescence promoting endothelial dysfunction and, ultimately, cardiovascular events. Circulating microvesicles (MVs) of patients with acute coronary syndrome promoted premature endothelial senescence by stimulating the local angiotensin system. Omega 3 PUFAs have been shown to reduce the risk of cardiovascular disease in patients at high risk.
Purpose
This study investigated whether a 7-day intake of the omega 3 formulation EPA:DHA 6:1 by rats affects the level of MVs released by spleen-derived cultured leukocytes as well as their ability to promote premature senescence in target endothelial cells (ECs), and, if so, to clarify the underlying mechanism.
Methods
Middle-aged male Wistar rats (M, 48-week old) received 500 mg/kg/d of either EPA:DHA 6:1, EPA:DHA 1:1, or vehicle (CTL) for 7 days. Thereafter, spleen-derived leukocytes, a rich source of MVs, were prepared and cultured for 24 h. Cultured ECs were prepared from porcine coronary arteries. Senescence-associated β-galactosidase activity (SA-β-gal) was assessed by C12FDG, protein expression level by Western blot analysis, oxidative stress by dihydroethidium using confocal microscopy, and procoagulant MVs by prothrombinase assay. Spleen-derived leukocytes from untreated young (Y, 12-week) and old (O, 72-week) rats were also studied.
Results
Shedding of MVs by spleen-derived leukocytes significantly increased with increasing age. Incubation of ECs with leukocyte-derived MVs (10 nM Phtd Ser eq.) from M and O but not those from Y induced premature senescence after 48 h. The stimulatory effect of M-MVs was prevented by losartan and associated with oxidative stress. M-MVs induced an upregulation of senescence markers (p16, p21, p53), pro-atherothrombotic markers (VCAM-1, ICAM-1, tissue factor), the pro-inflammatory marker cyclooxygenase-2 (COX-2) but not COX-1, and of the angiotensin system (angiotensin-converting enzyme and type 1 angiotensin receptor), whereas endothelial NO synthase was down-regulated. A one-week intake of EPA:DHA 1:1 and 6:1 by M rats decreased the leukocyte-derived MVs shedding by about 14% and 24%, and EPA:DHA 6:1 reduced their ability to induce ECs senescence by 38%. The stimulatory effect of M-MVs on the expression of target proteins was also observed with those from the EPA:DHA 1:1 but not with those from the 6:1 group.
Conclusion
These findings indicate that ingestion of EPA:DHA 6:1 by middle-aged rats reduces not only the shedding of MVs by spleen-derived leukocytes but also their ability to induce pro-senescent, pro-thrombotic and pro-inflammatory responses in endothelial cells most likely by decreasing the local angiotensin system. They further suggest that EPA:DHA 6:1 may help to delay ageing-related endothelial dysfunction.
Acknowledgement/Funding
Unrestricted research grant from PIVOTAL Therapeutics Inc.
Collapse
Affiliation(s)
- A W Qureshi
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - R Altamimy
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - A El Habhab
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - L Amoura
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - S Khemais-Berkhiat
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - M Kassem
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - M A Farooq
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - H Hasan
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - S.-H Park
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - F El Ghazouani
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - C Auger
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - V B Schini-Kerth
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| | - F Toti
- University of strasbourg, UMR 1260 INSERM, Faculty of pharmacy, Illkirch, France
| |
Collapse
|
10
|
Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, Park SH, Amoura L, Abbas M, Auger C, Kessler L, Mayoux E, Toti F, Schini-Kerth VB. Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med 2019; 24:2109-2122. [PMID: 30929316 PMCID: PMC7011151 DOI: 10.1111/jcmm.14233] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 12/20/2018] [Accepted: 01/29/2019] [Indexed: 01/01/2023] Open
Abstract
High glucose (HG)-induced endothelial senescence and dysfunction contribute to the increased cardiovascular risk in diabetes. Empagliflozin, a selective sodium glucose co-transporter2 (SGLT2) inhibitor, reduced the risk of cardiovascular mortality in type 2 diabetic patients but the protective mechanism remains unclear. This study examines the role of SGLT2 in HG-induced endothelial senescence and dysfunction. Porcine coronary artery cultured endothelial cells (ECs) or segments were exposed to HG (25 mmol/L) before determination of senescence-associated beta-galactosidase activity, protein level by Western blot and immunofluorescence staining, mRNA by RT-PCR, nitric oxide (NO) by electron paramagnetic resonance, oxidative stress using dihydroethidium and glucose uptake using 2-NBD-glucose. HG increased ECs senescence markers and oxidative stress, down-regulated eNOS expression and NO formation, and induced the expression of VCAM-1, tissue factor, and the local angiotensin system, all these effects were prevented by empagliflozin. Empagliflozin and LX-4211 (dual SGLT1/2 inhibitor) reduced glucose uptake stimulated by HG and H2 O2 in ECs. HG increased SGLT1 and 2 protein levels in cultured ECs and native endothelium. Inhibition of the angiotensin system prevented HG-induced ECs senescence and SGLT1 and 2 expression. Thus, HG-induced ECs ageing is driven by the local angiotensin system via the redox-sensitive up-regulation of SGLT1 and 2, and, in turn, enhanced glucotoxicity.
Collapse
Affiliation(s)
- Sonia Khemais-Benkhiat
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Eugenia Belcastro
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Noureddine Idris-Khodja
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France.,UMR INSERM 1109, Nanomédecine Régénérative Ostéo-articulaire et Dentaire, Faculté de Médecine, FMTS, Université de Strasbourg, Strasbourg, France
| | - Sin-Hee Park
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Lamia Amoura
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Malak Abbas
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Cyril Auger
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Laurence Kessler
- EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, FMTS, Université de Strasbourg, Illkirch, France
| | - Eric Mayoux
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Florence Toti
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| | - Valérie B Schini-Kerth
- UMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France
| |
Collapse
|
11
|
Gaertner S, Farooq MA, Pollet B, Amoura L, Khemais-Benkhiat S, Park S, Geny B, Toti F, Stephan D, Auger C, Schini-Kerth VB. P2622Ageing-related endothelial dysfunction in the femoral vein is mediated by cyclooxygenases: Role of thromboxane prostanoid receptors. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Gaertner
- University Hospital of Strasbourg, Department of Vascular Diseases and Hypertension, Strasbourg, France
| | - M A Farooq
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - B Pollet
- University of Strasbourg, CNRS UMR 7021, Laboratory of Bioimaging and Pathologies, Strasbourg, France
| | - L Amoura
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - S Khemais-Benkhiat
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - S Park
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - B Geny
- University of Strasbourg, EA 3072, Mitochondrie, Stress oxydant et Protection musculaire, Strasbourg, France
| | - F Toti
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - D Stephan
- University Hospital of Strasbourg, Department of Vascular Diseases and Hypertension, Strasbourg, France
| | - C Auger
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| | - V B Schini-Kerth
- University of Strasbourg, INSERM UMR 1260, Regenerative Nanomedicine, Strasbourg, France
| |
Collapse
|
12
|
Park S, Khemais-Benkhiat S, Idris-Khodja N, Amoura L, Abbas M, Auger C, Kessler L, Mayoux E, Toti F, Schini-Kerth V. Upregulation of sodium-glucose cotransporter 2 (SGLT2) expression in cultured senescent endothelial cells and in arterial sites at risk in vivo in rats. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Altamimy R, Qureshi A, Amoura L, El Habhab A, El Itawi H, Kassem M, Khemais S, Pollet B, El-Ghazouani F, Auger C, Schini-Kerth V, Toti F. Leukocyte-derived microparticles exaggerate endothelial senescence and vascular dysfunction induced by high glucose. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
14
|
Farooq MA, Amoura L, Gaertner S, Niazi ZR, Park S, Qureshi AW, Oak MH, Toti F, Schini-Kerth VB, Auger C. O38 The omega-3 EPA:DHA 6:1 formulation improves ageing-related blunted endothelium-dependent relaxations and increased contractile responses in the mesenteric artery: Role of oxidative stress and cyclooxygenases. Biochem Pharmacol 2017. [DOI: 10.1016/j.bcp.2017.06.103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Farooq M, Amoura L, Gaertner S, Niazi Z, Park S, Qureshi A, Oak M, Toti F, Schini-Kerth V, Auger C. P3472Oral intake of EPA:DHA 6:1 improves ageing-related blunted endothelium-dependent relaxations and increased contractile responses in the mesenteric artery: role of oxidative stress and cyclooxygenases. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Kreutter G, Kassem M, El Habhab A, Baltzinger P, Abbas M, Boisrame-Helms J, Amoura L, Peluso J, Yver B, Fatiha Z, Ubeaud-Sequier G, Kessler L, Toti F. Endothelial microparticles released by activated protein C protect beta cells through EPCR/PAR1 and annexin A1/FPR2 pathways in islets. J Cell Mol Med 2017; 21:2759-2772. [PMID: 28524456 PMCID: PMC5661261 DOI: 10.1111/jcmm.13191] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Accepted: 03/12/2017] [Indexed: 01/08/2023] Open
Abstract
Islet transplantation is associated with early ischaemia/reperfusion, localized coagulation and redox‐sensitive endothelial dysfunction. In animal models, islet cytoprotection by activated protein C (aPC) restores islet vascularization and protects graft function, suggesting that aPC triggers various lineages. aPC also prompts the release of endothelial MP that bear EPCR, its specific receptor. Microparticles (MP) are plasma membrane procoagulant vesicles, surrogate markers of stress and cellular effectors. We measured the cytoprotective effects of aPC on endothelial and insulin‐secreting Rin‐m5f β‐cells and its role in autocrine and paracrine MP‐mediated cell crosstalk under conditions of oxidative stress. MP from aPC‐treated primary endothelial (EC) or β‐cells were applied to H2O2‐treated Rin‐m5f. aPC activity was measured by enzymatic assay and ROS species by dihydroethidium. The capture of PKH26‐stained MP and the expression of EPCR were probed by fluorescence microscopy and apoptosis by flow cytometry. aPC treatment enhanced both annexin A1 (ANXA1) and PAR‐1 expression in EC and to a lesser extent in β‐cells. MP from aPC‐treated EC (eMaPC) exhibited high EPCR and annexin A1 content, protected β‐cells, restored insulin secretion and were captured by 80% of β cells in a phosphatidylserine and ANXA1‐dependent mechanism. eMP activated EPCR/PAR‐1 and ANXA1/FPR2‐dependent pathways and up‐regulated the expression of EPCR, and of FPR2/ALX, the ANXA1 receptor. Cytoprotection was confirmed in H2O2‐treated rat islets with increased viability (62% versus 48% H2O2), reduced apoptosis and preserved insulin secretion in response to glucose elevation (16 versus 5 ng/ml insulin per 10 islets). MP may prove a promising therapeutic tool in the protection of transplanted islets.
Collapse
Affiliation(s)
- Guillaume Kreutter
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France
| | - Mohamad Kassem
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,UMR7213 CNRS, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Ali El Habhab
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,UMR7213 CNRS, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Philippe Baltzinger
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,Department of Diabetology, University Hospital, CHU de Strasbourg, 1 place de l'Hôpital, Strasbourg Cedex, France
| | - Malak Abbas
- UMR7213 CNRS, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Julie Boisrame-Helms
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,Department of Anesthesia-Reanimation, University Hospital, CHU de Strasbourg, 1 place de l'Hôpital, Strasbourg Cedex, France
| | - Lamia Amoura
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,UMR7213 CNRS, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Jean Peluso
- UPS1401- Plateforme eBiocyte, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Blandine Yver
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France
| | - Zobairi Fatiha
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France
| | - Geneviève Ubeaud-Sequier
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,Department of Pharmacy-sterilization, University Hospital, CHU de Strasbourg, Strasbourg, France.,UPS1401- Plateforme eBiocyte, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| | - Laurence Kessler
- EA7293, Vascular and Tissular Stress in Transplantation, Federation of Translational Medicine of Strasbourg, Faculty of Medicine, University of Strasbourg, Illkirch, France.,Department of Diabetology, University Hospital, CHU de Strasbourg, 1 place de l'Hôpital, Strasbourg Cedex, France
| | - Florence Toti
- UMR7213 CNRS, Laboratory of Biophotonics and Pharmacology, Faculty of Pharmacy, University of Strasbourg, Illkirch, France
| |
Collapse
|
17
|
Abbas M, Jesel L, Auger C, Amoura L, Messas N, Manin G, Rumig C, León-González AJ, Ribeiro TP, Silva GC, Abou-Merhi R, Hamade E, Hecker M, Georg Y, Chakfe N, Ohlmann P, Schini-Kerth VB, Toti F, Morel O. Endothelial Microparticles From Acute Coronary Syndrome Patients Induce Premature Coronary Artery Endothelial Cell Aging and Thrombogenicity: Role of the Ang II/AT1 Receptor/NADPH Oxidase-Mediated Activation of MAPKs and PI3-Kinase Pathways. Circulation 2016; 135:280-296. [PMID: 27821539 DOI: 10.1161/circulationaha.116.017513] [Citation(s) in RCA: 88] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 10/19/2016] [Indexed: 01/01/2023]
Abstract
BACKGROUND Microparticles (MPs) have emerged as a surrogate marker of endothelial dysfunction and cardiovascular risk. This study examined the potential of MPs from senescent endothelial cells (ECs) or from patients with acute coronary syndrome (ACS) to promote premature EC aging and thrombogenicity. METHODS Primary porcine coronary ECs were isolated from the left circumflex coronary artery. MPs were prepared from ECs and venous blood from patients with ACS (n=30) and from healthy volunteers (n=4) by sequential centrifugation. The level of endothelial senescence was assessed as senescence-associated β-galactosidase activity using flow cytometry, oxidative stress using the redox-sensitive probe dihydroethidium, tissue factor activity using an enzymatic Tenase assay, the level of target protein expression by Western blot analysis, platelet aggregation using an aggregometer, and shear stress using a cone-and-plate viscometer. RESULTS Senescence, as assessed by senescence-associated β-galactosidase activity, was induced by the passaging of porcine coronary artery ECs from passage P1 to P4, and was associated with a progressive shedding of procoagulant MPs. Exposure of P1 ECs to MPs shed from senescent P3 cells or circulating MPs from ACS patients induced increased senescence-associated β-galactosidase activity, oxidative stress, early phosphorylation of mitogen-activated protein kinases and Akt, and upregulation of p53, p21, and p16. Ex vivo, the prosenescent effect of circulating MPs from ACS patients was evidenced only under conditions of low shear stress. Depletion of endothelial-derived MPs from ACS patients reduced the induction of senescence. Prosenescent MPs promoted EC thrombogenicity through tissue factor upregulation, shedding of procoagulant MPs, endothelial nitric oxide synthase downregulation, and reduced nitric oxide-mediated inhibition of platelet aggregation. These MPs exhibited angiotensin-converting enzyme activity and upregulated AT1 receptors and angiotensin-converting enzyme in P1 ECs. Losartan, an AT1 receptor antagonist, and inhibitors of either mitogen-activated protein kinases or phosphoinositide 3-kinase prevented the MP-induced endothelial senescence. CONCLUSIONS These findings indicate that endothelial-derived MPs from ACS patients induce premature endothelial senescence under atheroprone low shear stress and thrombogenicity through angiotensin II-induced redox-sensitive activation of mitogen-activated protein kinases and phosphoinositide 3-kinase/Akt. They further suggest that targeting endothelial-derived MP shedding and their bioactivity may be a promising therapeutic strategy to limit the development of an endothelial dysfunction post-ACS.
Collapse
Affiliation(s)
- Malak Abbas
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Laurence Jesel
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Cyril Auger
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Lamia Amoura
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Nathan Messas
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Guillaume Manin
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Cordula Rumig
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Antonio J León-González
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Thais P Ribeiro
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Grazielle C Silva
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Raghida Abou-Merhi
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Eva Hamade
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Markus Hecker
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Yannick Georg
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Nabil Chakfe
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Patrick Ohlmann
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Valérie B Schini-Kerth
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Florence Toti
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.)
| | - Olivier Morel
- From UMR CNRS 7213 Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France (M.A., L.J., C.A., L.A., A.J.L.-G., T.P.R., G.C.S., V.B.S.-K., F.T., O.M.); EA7293 Stress Vasculaire et Tissulaire en Transplantation, Faculté de Pharmacie, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Illkirch, France (M.A., L.J., L.A.); Faculté des Sciences I. Laboratoire Génomique et Santé, Plateforme de Recherche en Sciences et Technologies, Université Libanaise, Hadath, Lebanon )M.A., R.A.-M., E.H.); Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Fédération de Médecine Translationnelle de Strasbourg, France (N.M., G.M., Y.G., N.C., P.O., O.M.); and Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, University of Heidelberg, Germany (C.R., M.H.).
| |
Collapse
|